Share Email Print
cover

Proceedings Paper

Effect of the FDA on health care investments
Author(s): David J. Cleary
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The cost of securing FDA approval has long been an important consideration in funding projects involving new medical technologies, but the more stringent regulatory behavior of the FDA in the past few years has led to a discernable decrease in the funding of start-up medical device companies. An abundance of anecdotal evidence, supported with surveys of venture capital firms, investment groups and medical device corporations, indicates a serious shortage of funds available for the development of certain medical technologies.

Paper Details

Date Published: 6 December 1994
PDF: 5 pages
Proc. SPIE 2307, Health Care Technology Policy I: The Role of Technology in the Cost of Health Care, (6 December 1994); doi: 10.1117/12.195462
Show Author Affiliations
David J. Cleary, Cleary & Oxford Associates (United States)


Published in SPIE Proceedings Vol. 2307:
Health Care Technology Policy I: The Role of Technology in the Cost of Health Care
Warren S. Grundfest, Editor(s)

© SPIE. Terms of Use
Back to Top